The two major goals of oral cancer chemoprevention efforts are the ability to segregate the high-risk patients and the identification of an effective pharmacologic agent that halts progression to invasive cancer. Considerable progress has recently been achieved in profiling invasive head and neck squamous cell carcinomas, particularly with the use of high throughput technologies. Similar molecular characterization of potentially malignant oral epithelial lesions (OPMLs) [leukoplakia and erythroplakia] is yet to be accomplished. It is postulated, though, that molecular profiling could lead to the discovery of novel markers of cancer risk that could also serve as potential targets for chemoprevention. In this perspective, we comment on the work by Izumchenko et al.
Introduction
Central to successful oral cancer chemoprevention efforts are identification of a highrisk subset and finding a pharmacologic agent that can effectively halt the process of oral carcinogenesis. Oral potentially malignant lesions (OPMLs) are clinically recognized as leukoplakia and erythroplakia. However, accurate prediction of their progression within and between subjects is currently elusive. A variable risk of malignant transformation of leukoplakias has been reported in the literature, with geography (and most likely etiologic factors) playing a major role in influencing the incidence of invasive cancer development. In a populational-based study in India (where betel nut chewing and use of smokeless tobacco is very prevalent), the rate of malignant transformation was reported at 0.06% per year (1) , whereas this figure seems to be higher in hospital-based studies in the Western world (2) . The presence of dysplasia of moderate to severe degrees is commonly used in risk assessment and as an indication for surgical resection of leukoplakias. This strategy, however, is suboptimal at several levels: the correlation between dysplasia and subsequent invasive cancer development is not perfect -there is great variability in the classification of dysplastic lesions among pathologists, and surgical resection may not address the remainder of the mucosa exposed to the field-cancerization effect still at risk for oral cancer (3).
The underlying molecular events of oral carcinogenesis have been the subject of According to this model, activation of oncogenes and inactivation of tumor suppressor genes lead to progression of premalignant lesions to invasive cancers; specific genetic events may occur in a distinct order of progression; and the accumulation of these genetic events, rather than the order in which they occur, ultimately determines malignant transformation (4) .
Similarly, a transcriptional progression model has been developed, demonstrating a clear separation in gene expression profiles between histologically normal mucosa, premalignant lesions, and invasive head and neck squamous cell carcinomas, with a close association of the transcriptome alterations between the latter two groups (5). However, a limitation of these previous studies was the small size and the inadequate sequential temporal sampling of progressive lesions. Although a temporal relation can be inferred on the basis of the histological appearance of the lesions, little is known about the associations of these OPML molecular alterations with cancer risk and their active participation in the process of malignant transformation (as opposed to being just passenger events and/or a reflection of chromosomal instability).
Nonetheless, these data provide a framework for further studies on the molecular evolution of OPMLs as they progress to invasive cancers, leading to potential discoveries on novel targets for oral cancer chemoprevention. that LOH at these loci was associated with a 5-fold increase in the risk of invasive cancer development (6) . Subsequent studies have confirmed these findings (7) (8) (9) .
Based on these seminal data, we launched and recently completed the first randomized, oral cancer chemoprevention clinical trial that included molecular risk stratification as an integral eligibility criterion -the Erlotinib Prevention of Oral Cancer (EPOC) study. In EPOC, patients with OPMLs (with or without a prior history of oral cancer) were tested for LOH at 3p14, 9p21 and additional chromosomal sites. If highrisk LOH profiles were identified, patients were randomized to receive placebo versus erlotinib for 12 months, with a primary endpoint of oral cancer-free survival. LOHnegative patients were not treated on study but monitored for oral cancer development. to identify novel prognostic markers in OPMLs that [1] are fully characterized preclinically and clinically, in regards to their role in oral carcinogenesis, and [2] can not only help predict the risk of invasive cancer, but also serve, at the same time, as targets for pharmacologic intervention.
The availability of high throughput genomic analysis and their applications in head and neck squamous cell carcinomas (profiling for the most part oral cavity cancers) has provided detailed information on the genomic spectrum of these tumors. The most common somatic mutations identified in one of the initial high throughput sequencing studies of invasive head and neck cancers occurred in the genes TP53, NOTCH1, CDKN2A, PIK3CA, FBXW7, and HRAS at frequencies of 47, 15, 9, 6, 5, and 4%, respectively. Of the 28 NOTCH1 mutations observed, 11 were predicted to truncate the protein product, and therefore probably represent inactivating mutations, whereas 17 were missense mutations (12) . These findings were, for the most part, recapitulated in independent cohorts (13-15). As genomic characterization efforts evolve, geographic represent the first report of a targetable gain-of-function mutation that actively participates in the process of oral carcinogenesis. One could easily envision a chemoprevention strategy according to which patients with OPMLs would be sequenced for the NOTCH1 gene, and if an activating mutation were identified, they would be exposed to a NOTCH1 inhibitor. While, at this time, it is unclear whether this would only be applicable to ethnic Chinese populations, this could conceivably be the first example, in oral cancer prevention, that a possible marker of cancer risk and driver of carcinogenesis is targeted to suppress invasive cancer development. This clearly addresses the aforementioned EPOC trial limitation, characterized by the risk markertarget dissociation.
The work by Izumchenko et al. also illustrates the need for extensive molecular profiling of OPMLs in an attempt to improve chemoprevention strategies. We envision that the following steps will be key to streamline drug development in this field:
[1] Sequencing of large cohorts of clinically annotated specimens, with long term follow up and information on ethnicity, environmental and tobacco / alcohol exposure to identify other potential markers of cancer risk that can be targeted in a personalized way;
[2] Analysis of the temporal progression of molecular changes within and across patients; [3] Integrative multi-platform studies of the molecular pathways in OPMLs to identify pharmacologic strategies targeted at key driver events. 
